Results 171 to 180 of about 54,679 (264)

Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma

Liver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Durvalumab plus tremelimumab (Dur/Tre) is the first‐line treatment for unresectable hepatocellular carcinoma (uHCC). Immune‐mediated adverse events (imAEs) are common; however, the impact of specific imAE types on treatment persistence and outcomes remains unclear.
Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Takanori Matsuura, Yoshihide Ueda, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, on behalf of the RELPEC Group and HCC 48 Group   +53 more
wiley   +1 more source

Comparative Genomic Profiling and Prognostic Impact in Recurrent and/or Metastatic Hypopharyngeal and Esophageal Squamous Cell Carcinoma

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 3, June 2026.
ABSTRACT Objective This study aimed to characterize the mutational profile of recurrent and/or metastatic esophageal squamous cell carcinoma (ESCC) and hypopharyngeal squamous cell carcinoma (HPSCC). Methods Data from 1319 consecutive patients with ESCC and 195 patients with HPSCC registered in the Center for Cancer Genomics and Advanced Therapeutics ...
Hiromi Nagano, Satoshi Kiyama, Takayuki Kyutoku, Hayato Matsumoto, Masaru Yamashita   +4 more
wiley   +1 more source

A "one-two punch" strategy to reverse immunosuppressive metabolism and activate T-cell immunity for enhanced cancer checkpoint immunotherapy. [PDF]

J Nanobiotechnology
Chang P, Tian K, Yang X, Chen D, Wang C, Li K, Chen D, Feng Y, Zeng Y, Zhan Y, Zhan W.   +10 more
europepmc   +1 more source

Radiotherapy and Immune System Interactions Historical Perspectives and Clinical Advancements

Molecular Carcinogenesis, Volume 65, Issue 6, Page 649-664, June 2026.
ABSTRACT Radiotherapy (RT) has evolved significantly since its inception from treating benign conditions to becoming a cornerstone of cancer treatment. This review examines the complex interactions between RT and the immune system, highlighting its diverse effects on various immune cell populations, and exploring emerging strategies to enhance ...
Safiy Yahia, Ayman J. Oweida, Houda Bahig, Daniel Taussky   +3 more
wiley   +1 more source

Complete Response to Nivolumab-Relatlimab Following Progression of Invasive Sinonasal Mucosal Melanoma on First-Line Nivolumab-Ipilimumab: A Case Report. [PDF]

Cancer Rep (Hoboken)
Patel R, Post-Zwicker L, Kaur V.
europepmc   +1 more source

Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies

MedComm, Volume 7, Issue 6, June 2026.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by unleashing antitumor immunity. This review comprehensively examines the molecular mechanisms underlying key immune checkpoints—including PD‐1/PD‐L1, CTLA‐4, and TIM‐3—and their clinical applications.
Qintao Ge, Liu Yu, Jiahe Lu, Aihetaimujiang Anwaier, Xiyue Xiao, Yonghao Chen, Dingwei Ye, Hailiang Zhang, Wenhao Xu, Wenbin Dai   +9 more
wiley   +1 more source

Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis. [PDF]

Dermatol Ther (Heidelb)
Zarańska K, Kamińska-Winciorek G, Cortez AJ, Wąsik G, Gajda M.   +4 more
europepmc   +1 more source

Gastric Cancer: Pathobiology and Therapeutics

MedComm, Volume 7, Issue 6, June 2026.
Gastric cancer is a multistep process driven by the interplay of microbial virulence, host epithelial injury, and evolving molecular reprogramming. Initiation involves pathogen‐induced epigenetic alterations and the early subversion of key oncogenic signaling networks, facilitating the transition from chronic injury to metaplasia and malignant ...
Ruixian Yu, Miao Zhang, Yan Meng, Chunxiao Zhu, Weihong Zhang, Hui Zhang, Zhifa Cao, Meihang Du, Zhangting Zhao, Junping Bai, Yi Han, Yang Tang, Wei Kang, Ka Fai To, Shi Jiao, Liwei An, Zhaocai Zhou   +16 more
wiley   +1 more source

The cost-effectiveness of tumour-infiltrating lymphocyte cell therapy for advanced melanoma: a systematic review. [PDF]

BMC Cancer
Wu M, Larkin J, Furness A, Stavropoulou C.   +3 more
europepmc   +1 more source

Metabolic Regulation of Immune Responses: Molecular Mechanisms, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 6, June 2026.
FBP1 loss drives immune evasion and therapy resistance by enhancing glycolysis, STAT3 activation, and PD‐L1 expression, leading to T cell exhaustion and NK cell inhibition. FBP1 restoration, via LNP‐mRNA or epigenetic modulation, reverses these immunosuppressive effects, reactivates cytotoxic T cells, promotes M1 macrophage polarization, and enhances ...
Chunwei Li, Ziqiang Liu, Dezheng Kong, Zhengze Li, Yiming Yan, Yanyu Dong, Lili Zhu, JiaNing Cao, Zhirui Fan, Gautam Sethi, Lifeng Li   +10 more
wiley   +1 more source